palmidrol has been researched along with Depressive Disorder, Major in 4 studies
palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection
palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to assess the safety, tolerability and efficacy of palmitoylethanolamide (PEA) when dosed at 300 mg and 600 mg per day on symptoms of knee osteoarthritis." | 2.90 | A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. ( Steels, E; Venkatesh, R; Vitetta, G; Vitetta, L, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ghazizadeh-Hashemi, M | 1 |
| Ghajar, A | 1 |
| Shalbafan, MR | 1 |
| Ghazizadeh-Hashemi, F | 1 |
| Afarideh, M | 1 |
| Malekpour, F | 1 |
| Ghaleiha, A | 1 |
| Ardebili, ME | 1 |
| Akhondzadeh, S | 1 |
| Steels, E | 2 |
| Venkatesh, R | 1 |
| Vitetta, G | 1 |
| Vitetta, L | 1 |
| Meyer, JD | 1 |
| Crombie, KM | 1 |
| Cook, DB | 1 |
| Hillard, CJ | 2 |
| Koltyn, KF | 1 |
| Hill, MN | 1 |
| Miller, GE | 1 |
| Carrier, EJ | 1 |
| Gorzalka, BB | 1 |
2 trials available for palmidrol and Depressive Disorder, Major
| Article | Year |
|---|---|
Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial.
Topics: Adult; Amides; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Chemotherapy, Adjuvan | 2018 |
A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis.
Topics: Adult; Aged; Amides; Anti-Inflammatory Agents, Non-Steroidal; Depressive Disorder, Major; Double-Bli | 2019 |
2 other studies available for palmidrol and Depressive Disorder, Major
| Article | Year |
|---|---|
Serum Endocannabinoid and Mood Changes after Exercise in Major Depressive Disorder.
Topics: Adult; Affect; Amides; Arachidonic Acids; Depressive Disorder, Major; Endocannabinoids; Ethanolamine | 2019 |
Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress.
Topics: Adult; Amides; Arachidonic Acids; Cannabinoid Receptor Modulators; Case-Control Studies; Depressive | 2009 |